Summit Therapeutics plc
('Summit' or 'the Company')
RESULT OF ANNUAL GENERAL MEETING
Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that all resolutions proposed to shareholders at the Company's Annual General Meeting ('AGM') held earlier today were duly passed. The results of the proxy votes lodged in advance and at the meeting will be available shortly from the Investors section of Summit's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880
N+1 Singer
(Broker)
Aubrey Powell / Lauren Kettle Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications Tel: +1 781 235 3060
(US media contact) ksharma@macbiocom.com
Karen Sharma
Consilium Strategic Communications Tel: +44 (0)20 3709 5700 (Financial public relations, UK) summit@consilium-comms.com Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via GlobeNewswire
A0DKWDBN40HZ0R18
Copyright RTT News/dpa-AFX